Table 1.
Prevalence of celiac disease-specific antibodies in IBD and control
| Crohn’s disease | Ulcerative colitis | Control | Total | |||
|---|---|---|---|---|---|---|
| Number of patients | (n = 62) | p value* | (n = 110) | p value** | (n = 190) | (n = 362) |
| Elevated serum celiac disease-specific antibodies, n (%) | ||||||
| tTG alone | 3 (4.8) | <0.001 | 5 (4.5) | <0.001 | 2 (1.1) | 10 |
| DGP alone | 3 (4.8) | <0.001 | 6 (4.5) | <0.001 | 0 (0) | 9 |
| Both tTG and DGP | 9 (14.5) | <0.001 | 5 (4.5) | <0.001 | 1 (0.5) | 15 |
| Negative for any serum celiac disease-specific antibodies, n (%) | 47 (75.9) | <0.001 | 94 (85.5) | <0.001 | 187 (98.4) | 328 |
tTG serum tissue trans glutaminase (IgA), DGP serum deamidated gliadin peptide (IgA)
* Statistical comparisons between Crohn’s disease and control
** Statistical comparisons between ulcerative colitis and control